should be entered.

CORRESPONDENCE ADDRESS:

Please note change of correspondence address:

Kathleen M. Williams, Ph.D.
Customer Number: 27495
Palmer & Dodge LLP
One Beacon Street
Boston, MA 02108

To reach Dr. Williams by telephone or facsimile transmission, please use the following numbers: telephone (617) 573-0451 or facsimile (617) 227-4420.

CONCLUSION

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Respectfully submitted,

Date: 9/7/01



Kathleen M. Williams
Reg. No.: 34,380
PALMER AND DODGE, LLP
One Beacon Street
Boston, MA 02108
(617) 573-0100

Marked-Up Version of Page 22 Paragraph Showing Changes Made

A similar analysis can differentiate a human Th1 from a Th2 response. One examines inflamed tissue, isolated leukocytes from regions of inflammation and peripheral blood cells. Leukocytes are cultured in vitro alone or in the presence of parasite antigen or mitogens to stimulate cytokine release, and the cytokines are analyzed by, for example, ELISA. The specific pattern of cytokines released allows differentiation of Th1 from Th2 responses. IgG2 is generally indicative of a Th1 response, whereas IgE[,] and IgG1 [or IgG2] are indicative of Th2 response.

Marked-Up Version of Page 49 Section Showing Changes Made

In the first experiments, two experimental protocols have been optimized to characterize the effect of schistosome ova injection on EAE. The two protocols are different only in the frequency of high or low dose immunization with schistosome ova. In Protocol #1, 6-8 week old female SJL/J mice were injected intraperitoneally with 10,000 schistosome ova fourteen days prior to EAE induction. Schistosome ova injection was repeated at day 4 prior to EAE induction using 5000 schistosome ova intraperitoneally and 5000 subcutaneously. This protocol had been shown to induce a very strong Th2 type immune response. On the day of EAE induction (day 0), the experimental animals were injected by subcutaneous tail base injection of 50 ug of PLP139-151 (HSLGKWGHPDKF) (SEQ ID NO. 1) peptide in CFA containing 1 mg